Organon &

Organon & ROCE

The Return on Capital Employed (ROCE) of Organon & (OGN) as of Oct 15, 2026 is 123.54 %. In the previous year, Return on Capital Employed (ROCE) was 281.14 % — a change of -56.06% (lower).

ROCE

123.54 %

YoY

-56.06%

Last updated:

In 2025, Organon &'s return on capital employed (ROCE) was 123.54 %, a -56.06% increase from the 281.14 % ROCE in the previous year.

The Organon & ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
42.63 USD
Jan 1, 2019
54.68 USD
Jan 1, 2020
51.90 USD
Jan 1, 2021
-126.99 USD
Jan 1, 2022
-191.14 USD
Jan 1, 2023
-1,714.29 USD
Jan 1, 2024
281.14 USD
Jan 1, 2025
123.54 USD
The Organon & ROCE history
YEARROCEYoY
123.54 %-56.06%
281.14 %-116.40%
-1,714.29 %+796.86%
-191.14 %+50.52%
-126.99 %-344.70%
51.90 %-5.10%
54.68 %+28.28%
42.63 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Organon & Stock analysis

What does Organon & do? Organon & Co., trading under the ticker symbol OGN and identified by ISIN US68622V1061, stands as a prominent entity within the global healthcare sector, specifically categorized under the pharmaceuticals industry. Headquartered in Jersey City, New Jersey, the United States, the company operates as a science-based global pharmaceutical organization dedicated to developing and delivering innovative health solutions. Since its initial public offering on May 14, 2021, Organon has established itself as a significant player in the market, employing approximately 10,000 full-time staff members who contribute to its extensive research, development, and commercialization efforts. The firm’s strategic focus is centered on a robust portfolio of prescription therapies and medical devices, primarily targeting three key therapeutic areas: women’s health, biosimilars, and established brands. In the realm of women’s health, Organon offers a diverse array of contraception and fertility products. Notable brands within this segment include Nexplanon, Implanon NXT, and NuvaRing, which address various contraceptive needs, alongside fertility treatments such as Follistim AQ and Elonva. These products are designed to provide comprehensive care for patients seeking reproductive health solutions. The company’s biosimilars portfolio is equally substantial, spanning critical treatments in immunology and oncology. This segment reflects Organon’s commitment to providing high-quality, accessible alternatives to biologic medicines, thereby supporting broader patient access to essential therapies. Additionally, the established brands division encompasses a wide range of products in cardiovascular, respiratory, dermatology, and non-opioid pain management. These legacy brands continue to serve a global patient base, ensuring continuity of care for chronic and acute conditions. Organon distributes its products through a multifaceted channel strategy, engaging with drug wholesalers and retailers, hospitals, government agencies, and managed healthcare providers. This includes partnerships with health maintenance organizations and pharmacy benefit managers, ensuring that its innovative solutions reach healthcare institutions and individual patients efficiently. By leveraging its scientific expertise and extensive distribution network, Organon & Co. aims to improve health outcomes worldwide, maintaining its position as a vital contributor to the global pharmaceutical landscape. Organon & is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Organon &'s Return on Capital Employed (ROCE)

Organon &'s Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Organon &'s ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Organon &'s ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Organon &’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Organon & stock

Return on Capital Employed (ROCE) of Organon & is 123.54 % in 2025.

Return on Capital Employed (ROCE) of Organon & changed from 281.14 % to 123.54 %, representing a -56.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Organon & since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Organon & with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Organon &

All Key Metrics — Organon &